US FDA approves painkillers designed to eliminate risk of addiction associated with opioids
New York: US federal officials have approved a new type of pain pill designed to eliminate the risks of addiction and overdose associated with opioid medications like Vicodin and OxyContin. The US Food and Drug Administration (FDA) said on Thursday it approved Vertex Pharmaceuticals’ Journavx for short-term pain that often follows surgery or injuries, Xinhua


New York: US federal officials have approved a new type of pain pill designed to eliminate the risks of addiction and overdose associated with opioid medications like Vicodin and OxyContin.
The US Food and Drug Administration (FDA) said on Thursday it approved Vertex Pharmaceuticals’ Journavx for short-term pain that often follows surgery or injuries, Xinhua news agency reported.
Journavx (suzetrigine) 50 milligram oral tablets, is the first drug to be approved in this new class of pain management medicines.
“Today’s approval is an important public health milestone in acute pain management,” said Jacqueline Corrigan-Curay, acting director of the US FDA’s Center for Drug Evaluation and Research.
“A new non-opioid analgesic therapeutic class for acute pain offers an opportunity to mitigate certain risks associated with using an opioid for pain and provides patients with another treatment option. This action and the agency’s designations to expedite the drug’s development and review underscore FDA’s commitment to approving safe and effective alternatives to opioids for pain management,” Corrigan-Curay said.
Journavx reduces pain by targeting a pain-signaling pathway involving sodium channels in the peripheral nervous system before pain signals reach the brain. But the medication’s modest effectiveness and lengthy development process underscore the challenges of finding new ways to manage pain, it noted.
Studies in more than 870 patients with acute pain due to foot and abdominal surgeries showed Vertex’s drug provided more relief than a dummy pill but didn’t outperform a common opioid-acetaminophen combination pill, it added.
The most common adverse reactions in study participants who received Journavx were itching, muscle spasms, increased blood levels of creatine phosphokinase, and rash.
Journavx is contraindicated for concomitant use with strong CYP3A inhibitors. In addition, patients should avoid food or drink containing grapefruit when taking Journavx.
–IANS
Odisha: ITDA Project Administrator Arrested for Possessing DA
Next ArticleJajpur: Police SI Nabbed for Taking Bribe
Related Articles
Sci & TechApple eyes $4 trillion market valuation amid robust iPhone 17 series sales
New Delhi: Riding on the stellar performance of the new iPhone 17 series, Apple is heading towards the $4 trillion market valuation, thus becoming the second-most valuable company after chip major Nvidia. Apple shares surged to an all-time high at $262.9 on Monday (US time). This took the company to a market valuation of nearly
Sci & TechData is the new oil, data centres new refineries: Ashwini Vaishnaw
New Delhi: Underlining India’s ambitious digital transformation agenda, Union Minister for Electronics and Information Technology, Ashwini Vaishnaw, on Saturday described data as “the new oil” and data centres as “the new refineries.” Speaking at the ‘NDTV Word Summit’ here, the minister emphasised the government’s vision of Aatmanirbharta, saying India aims to become self-sufficient in critical
Sci & TechUttarakhand to host precursor for India-AI Impact Summit on October 17
New Delhi: The Uttarakhand state government will hold the Uttarakhand AI Impact Summit 2025 on October 17 in Dehradun, in collaboration with the India AI Mission and the Ministry of Electronics and IT, the government informed on Thursday. The event is a pre-summit to the India-AI Impact Summit 2026, scheduled to take place on February
